Cytek Q2 Loss Deepens as Litigation Costs Surge Ahead of Trial
CTKB sits 23% above its 52-week low of $3.28.
Summary
Cytek Biosciences posted a wider Q2 net loss of $12.2 million as litigation expenses surged ahead of an August 17 patent trial. Revenue rose 6%, but escalating operating costs, especially legal fees, are eroding profitability.
Key Events · Earnings and Guidance · CTKB
-
Net Loss Widens
The Q2 net loss reached $12.2M, compared with $5.6M a year ago, while the six-month loss widened to $31.0M from $17.0M. Higher G&A expenses, mainly litigation costs, drove the increase.
-
Revenue Up 6%
Total revenue hit $48.1M, with product revenue up 4% and service revenue up 10%. Gross margin improved to 59% from 52%, aided by a one-time $2.8M tariff refund.
-
Litigation Costs Surge
General and administrative expenses jumped 24% to $16.8M, primarily due to higher litigation-related expenses from the Beckman Coulter patent infringement case. A trial is scheduled for August 17, 2026.
-
Cash Position
Cash, equivalents, and marketable securities totaled $262.0M at quarter-end, down slightly from $261.5M at year-end. Operating activities used $1.4M in cash during the first half.
Analysis · CTKB · Industrial Applications And Services
A sharp rise in legal expenses tied to the Beckman Coulter patent dispute more than doubled Cytek's net loss to $12.2 million in Q2. While revenue grew 6% to $48.1 million, the bottom line is under heavy pressure from costs that show no sign of easing — a trial is set for August 17, 2026. Adding to the expense burden, the company disclosed a $365,775 severance payment to its former chief legal officer. The balance sheet remains solid with $262 million in cash and securities, but the litigation overhang and widening losses dominate the narrative.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTKB was trading at $4.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $539.8M. The 52-week trading range was $3.28 to $6.18. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.